AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34329436 — intervention group
Group type: EXPERIMENTAL
Intervention: Role physical function and physical function
Number of subjects: 2783
Study 34329436 — intervention group
Group type: EXPERIMENTAL
Intervention: General health
Number of subjects: 2783
Study 34329576 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax added to CLIA (cladribine, high-dose cytarabine, idarubicin)
Number of subjects: 50
Study 34329576 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable (single-arm trial)
Number of subjects: 50
Study 34329772 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESERFLO® MicroShunt with adjunctive use of topical mitomycin C (MMC; 0.2-0.4 mg/ml) for 2-3 minutes
Number of subjects: 81
Study 34329772 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESERFLO® MicroShunt with adjunctive use of topical mitomycin C (MMC; 0.2 mg/ml)
Number of subjects: 81
Study 34329772 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESERFLO® MicroShunt with adjunctive use of topical mitomycin C (MMC; 0.4 mg/ml)
Number of subjects: 81
Study 34329772 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESERFLO® MicroShunt
Number of subjects: 81
Study 34329846 — intervention group
Group type: EXPERIMENTAL
Intervention: Budigalimab 375 mg via intravenous infusion every 3 weeks plus Rova-T 0.3 mg/kg intravenously on day 1 of the first and third 3-week cycle
Number of subjects: 31
Study 34329846 — intervention group
Group type: EXPERIMENTAL
Intervention: Budigalimab plus Rova-T in patients with high delta-like protein 3 expression
Number of subjects: 31
Study 34329939 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg b.i.d. + intravenous pegylated liposomal doxorubicin (PLD) 40 mg/m²
Number of subjects: 31
Study 34329939 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD 30 mg/m²
Number of subjects: 31
Study 34330322 — intervention group
Group type: EXPERIMENTAL
Intervention: Paquinimod 3 mg/day for 8 weeks
Number of subjects: 9
Study 34330416 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC/ESA algorithm classification in a higher-risk group
Number of subjects: 6976
Study 34330416 — intervention group
Group type: COMPARATOR
Intervention: Overuse or underuse of cardiac tests
Number of subjects: 6976
Study 34330416 — intervention group
Group type: COMPARATOR
Intervention: Test recommendation class for cardiac tests
Number of subjects: 6976
Study 34330417 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Assessment of Global activities in the Elderly (SAGE) scale
Number of subjects: 152
Study 34330671 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) applications targeting the atrial edge of the leak, average 18 ± 7 RF applications per patient, mean maximum contact force 16 ± 3 g, mean power 44 ± 2 W, mean RF time 5.1 ± 2.5 minutes.
Number of subjects: 43
Study 34330715 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant FOLFIRINOX × 8
Number of subjects: 25
Study 34330715 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation with carboplatin/paclitaxel
Number of subjects: 25
Study 34330715 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection after neoadjuvant treatment
Number of subjects: 25
Study 34330715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic complete response (pCR)
Number of subjects: 25
Study 34330715 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) analysis
Number of subjects: 25
Study 34330766 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (TVEC) with concurrent preoperative external beam radiation therapy (EBRT)
Number of subjects: 30
Study 34330766 — intervention group
Group type: COMPARATOR
Intervention: Control group (EBRT alone)
Number of subjects: 30
Study 34330766 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative outcomes
Number of subjects: 30
Study 34330786 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 1457
Study 34330786 — intervention group
Group type: COMPARATOR
Intervention: Other basal insulins
Number of subjects: 1457
Study 34330792 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 1221
Study 34330792 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional iron deficiency (ID)
Number of subjects: 1221
Study 34330792 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency anaemia (ID anaemia)
Number of subjects: 1221
Study 34330792 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency in untreated patients
Number of subjects: 1221
Study 34330792 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency in non-anaemic patients
Number of subjects: 1221
Study 34330842 — intervention group
Group type: EXPERIMENTAL
Intervention: ASTX029, a dual-mechanism ERK inhibitor
Number of subjects: 0
Study 34330842 — intervention group
Group type: EXPERIMENTAL
Intervention: ASTX029
Number of subjects: 0
Study 34330906 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 Chik vaccine (single intramuscular injection at one of three preestablished dosages)
Number of subjects: 24
Study 34330906 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 Chik vaccine (single intramuscular injection)
Number of subjects: 24
Study 34330906 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 Chik vaccine
Number of subjects: 24
Study 34330970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna dehydration (loss of 3% body weight)
Number of subjects: 20
Study 34330970 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drug (NSAID) intake
Number of subjects: 20
Study 34330970 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 20
Study 34331019 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV2 CONFIRMED infection
Number of subjects: 331
Study 34331019 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV2 SUSPECTED infection
Number of subjects: 331
Study 34331051 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine in ARD group
Number of subjects: 1092
Study 34331051 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 1092
Study 34331111 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib in combination with fludarabine plus cyclophosphamide (B-FC)
Number of subjects: 40
Study 34331258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg
Number of subjects: 622
Study 34331265 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients with ATTR amyloidosis
Number of subjects: 379
Study 34331265 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic Val30Met patients
Number of subjects: 379
Study 34331265 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic ATTRwt patients
Number of subjects: 379
Study 34331265 — intervention group
Group type: EXPERIMENTAL
Intervention: All symptomatic patients
Number of subjects: 379
Study 34331515 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF and MEK inhibitors
Number of subjects: 2
Study 34331548 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body computed tomography (WBCT)
Number of subjects: 10
Study 34331548 — intervention group
Group type: COMPARATOR
Intervention: Dual energy X-ray absorptiometry (DXA)
Number of subjects: 10
Study 34331588 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) item 1 (cough)
Number of subjects: 2046
Study 34331588 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) item 2 (phlegm)
Number of subjects: 2046
Study 34331588 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) item 5 (activities)
Number of subjects: 2046
Study 34331588 — intervention group
Group type: EXPERIMENTAL
Intervention: mMRC dyspnea scale
Number of subjects: 2046
Study 34331588 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional parameters and comorbidities
Number of subjects: 2046
Study 34331588 — intervention group
Group type: EXPERIMENTAL
Intervention: Item 8 (energy) in men
Number of subjects: 2046
Study 34331588 — intervention group
Group type: EXPERIMENTAL
Intervention: mMRC in men
Number of subjects: 2046
Study 34331588 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status in men
Number of subjects: 2046
Study 34331588 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI in men
Number of subjects: 2046
Study 34331588 — intervention group
Group type: EXPERIMENTAL
Intervention: Age in men
Number of subjects: 2046
Study 34331588 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometric lung function in men
Number of subjects: 2046
Study 34331588 — intervention group
Group type: EXPERIMENTAL
Intervention: Age in women
Number of subjects: 2046
Study 34331589 — intervention group
Group type: EXPERIMENTAL
Intervention: Anamorelin 100 mg orally daily with standardized physical activity and nutrition counseling for 43 days
Number of subjects: 45
Study 34332113 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical remodeling investigation
Number of subjects: 150
Study 34332113 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tissue gene expression
Number of subjects: 150
Study 34332113 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of COL8A2 and TNC
Number of subjects: 150
Study 34332113 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene panel including tissue KCNJ2, COL1A1, COL8A2, and EDN1
Number of subjects: 150
Study 34332154 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34332289 — intervention group
Group type: EXPERIMENTAL
Intervention: Online expressive writing intervention
Number of subjects: 63
Study 34332522 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the registry and management of in-hospital pediatric cardiac arrest.
Number of subjects: 0
Study 34332533 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome analysis using 3rd generation sequencing (Oxford Nanopore Technologies) for 16S rRNA and metagenomic sequencing.
Number of subjects: 400
Study 34332533 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome sequencing as a predictor of severity and course of acute pancreatitis.
Number of subjects: 400
Study 34332551 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients with ART
Number of subjects: 1026
Study 34332551 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients without ART
Number of subjects: 1026
Study 34332551 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-negative patients with COVID-19
Number of subjects: 1026
Study 34332558 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2i
Number of subjects: 440599
Study 34332614 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy (RCT)
Number of subjects: 32
Study 34332620 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside lower limb angiography combined with continuous NIRS monitoring
Number of subjects: 0
Study 34332620 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34332876 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 5764
Study 34332876 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated hemoglobin A1c (HbA1c)
Number of subjects: 5764
Study 34332876 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-DM)
Number of subjects: 5764
Study 34332992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-based adjuvant chemotherapy
Number of subjects: 21
Study 34333320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullying experiences (cyber, verbal-relational, physical) among adolescents with obesity
Number of subjects: 328
Study 34333320 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal-relational bullying experiences
Number of subjects: 328
Study 34333320 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical bullying experiences
Number of subjects: 328
Study 34333320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyberbullying experiences
Number of subjects: 328
Study 34333554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutetium-177 treatment
Number of subjects: 40
Study 34333603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing syndrome patients
Number of subjects: 50
Study 34333603 — intervention group
Group type: COMPARATOR
Intervention: Control individuals
Number of subjects: 50
Study 34334250 — intervention group
Group type: EXPERIMENTAL
Intervention: p75 neurotrophin receptor intervention
Number of subjects: 0
Study 34334250 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34334262 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured online training programme
Number of subjects: 245
Study 34334342 — intervention group
Group type: EXPERIMENTAL
Intervention: InterStim implant (de novo group)
Number of subjects: 291
Study 34334342 — intervention group
Group type: EXPERIMENTAL
Intervention: InterStim implant (replacement group)
Number of subjects: 291
Study 34334342 — intervention group
Group type: EXPERIMENTAL
Intervention: InterStim implant
Number of subjects: 291
Study 34334709 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported wheat sensitivity (SRWS)
Number of subjects: 496
Study 34334709 — intervention group
Group type: COMPARATOR
Intervention: Not-SRWS (Control)
Number of subjects: 496
Study 34334713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ustekinumab
Number of subjects: 31
Study 34335213 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer game-based rehabilitation treadmill platform (GRP) for dual-task (DT) assessment and training
Number of subjects: 30
Study 34335213 — intervention group
Group type: COMPARATOR
Intervention: Single task (ST) condition
Number of subjects: 30
Study 34335213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task (DT) condition
Number of subjects: 30
Study 34335213 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-3 group
Number of subjects: 30
Study 34335213 — intervention group
Group type: COMPARATOR
Intervention: PD-2 group
Number of subjects: 30
Study 34335219 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface electromyography based clinical assessment
Number of subjects: 0
Study 34335289 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training session
Number of subjects: 0
Study 34335289 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34335296 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP > 27.9
Number of subjects: 55
Study 34335296 — intervention group
Group type: COMPARATOR
Intervention: FFR < 0.75
Number of subjects: 55
Study 34335336 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention to promote positive mental health, details on dosage and duration not available.
Number of subjects: 0
Study 34335465 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose relacorilant (100-200 mg/d) for 12 weeks
Number of subjects: 34
Study 34335465 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose relacorilant (250-400 mg/d) for 16 weeks
Number of subjects: 34
Study 34335479 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning clustering based on AUCs of glucose and insulin during OGTT, and uric acid.
Number of subjects: 2495
Study 34335479 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypermetabolic obesity-hyperuricemia (HMO-U)
Number of subjects: 2495
Study 34335479 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypermetabolic obesity-hyperinsulinemia (HMO-I)
Number of subjects: 2495
Study 34335479 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypometabolic obesity (LMO)
Number of subjects: 2495
Study 34335479 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning clustering
Number of subjects: 2495
Study 34335606 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63/MVA Pfs25-IMX313
Number of subjects: 0
Study 34336750 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing intervention to engage older adults in balance workshops
Number of subjects: 0
Study 34336750 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34336760 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered care and gentle approach to treatment
Number of subjects: 18
Study 34336760 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication barriers
Number of subjects: 18
Study 34336760 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic barriers
Number of subjects: 18
Study 34336760 — intervention group
Group type: EXPERIMENTAL
Intervention: Good practice models
Number of subjects: 18
Study 34337153 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-management intervention
Number of subjects: 267
Study 34337278 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon 12.5 ng/kg/min
Number of subjects: 0
Study 34337278 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon 25 ng/kg/min
Number of subjects: 0
Study 34337278 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 34337406 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise
Number of subjects: 0
Study 34337406 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Diet
Number of subjects: 0
Study 34337406 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34337481 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage magnetic resonance imaging-guided transurethral ultrasound ablation (sTULSA)
Number of subjects: 11
Study 34337553 — intervention group
Group type: EXPERIMENTAL
Intervention: COVIDProtocols.org platform for developing and disseminating clinical guidelines
Number of subjects: 500000
Study 34337553 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Writing Application (CWA)
Number of subjects: 500000
Study 34337553 — intervention group
Group type: EXPERIMENTAL
Intervention: Web platform for content deployment
Number of subjects: 500000
Study 34337556 — intervention group
Group type: EXPERIMENTAL
Intervention: RH5 antibodies from human vaccine
Number of subjects: 0
Study 34337556 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34337972 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigenetic factors associated with gestational diabetes and macrosomia
Number of subjects: 0
Study 34338759 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 199
Study 34338759 — intervention group
Group type: COMPARATOR
Intervention: Single antiplatelet therapy (SAPT)
Number of subjects: 199
Study 34338965 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus Letrozole (PAL+LET)
Number of subjects: 1383
Study 34338965 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (LET)
Number of subjects: 1383
Study 34338965 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus Letrozole (PAL+LET) after propensity-score matching
Number of subjects: 1383
Study 34338965 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (LET) after propensity-score matching
Number of subjects: 1383
Study 34339017 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive management (PM) using calcipotriene 0.005%/betamethasone dipropionate 0.064% foam, twice-weekly during maintenance phase
Number of subjects: 0
Study 34339017 — intervention group
Group type: COMPARATOR
Intervention: Reactive management (RM) using vehicle foam
Number of subjects: 0
Study 34339261 — intervention group
Group type: EXPERIMENTAL
Intervention: Amivantamab
Number of subjects: 0
Study 34339292 — intervention group
Group type: EXPERIMENTAL
Intervention: Amivantamab
Number of subjects: 81
Study 34340209 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel tumor-normal genetic testing
Number of subjects: 0
Study 34340209 — intervention group
Group type: COMPARATOR
Intervention: Tumor-only testing
Number of subjects: 0
Study 34340523 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 0
Study 34340523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34340693 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based recruitment via social media
Number of subjects: 1971
Study 34340693 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up survey participation
Number of subjects: 1971
Study 34340693 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention rates
Number of subjects: 1971
Study 34340693 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trial implementation
Number of subjects: 1971
Study 34341101 — intervention group
Group type: EXPERIMENTAL
Intervention: Edinburgh Postnatal Depression Scale (EPDS) at NICU admission, discharge, 14 days and 30 days postdischarge
Number of subjects: 431
Study 34341101 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for postpartum depression during NICU stay
Number of subjects: 431
Study 34341101 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused attention on fathers
Number of subjects: 431
Study 34341142 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD20 therapies
Number of subjects: 119
Study 34341142 — intervention group
Group type: COMPARATOR
Intervention: DMTs other than anti-CD20
Number of subjects: 119
Study 34341142 — intervention group
Group type: COMPARATOR
Intervention: No DMT
Number of subjects: 119
Study 34341335 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (two doses)
Number of subjects: 276
Study 34341335 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222 vaccine (one dose)
Number of subjects: 276
Study 34341335 — intervention group
Group type: COMPARATOR
Intervention: MM patients
Number of subjects: 276
Study 34341335 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with anti-CD38 monoclonal antibodies or belantamab mafodotin
Number of subjects: 276
Study 34341335 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphopenia at the time of vaccination
Number of subjects: 276
Study 34342012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 12 weeks
Number of subjects: 18
Study 34342012 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline AI-BNST RSFC measurement
Number of subjects: 18
Study 34342022 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk alcohol use (AUDIT score ≥ 5)
Number of subjects: 105
Study 34342022 — intervention group
Group type: COMPARATOR
Intervention: Low-risk alcohol use (AUDIT score < 5)
Number of subjects: 105
Study 34342304 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0